相关临床试验
1045
78 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1833
进行中（未招募）
41
3.9%
已完成
638
61.0%
Enrolling By Invitation
10
1.0%
尚未招募
27
2.6%
招募中
102
9.8%
暂停
2
0.2%
终止
57
5.5%
Unknown
146
14.0%
撤回
22
2.1%
暂无批准数据
- The 2026 Ig Nobel Prizes were awarded on 3 September at a ceremony in Zurich, Switzerland, marking the first time in 36 years the event was held outside Boston. - The Chemistry prize recognized researchers who found cockroach milk proteins contain three times more energy than cow's milk proteins, using an X-ray free-electron laser. - The Biomechanics prize honored a team that defined kissing as non-agonistic oral–oral contact without food transfer, tracing the behavior back roughly 21.5 million years. - The Soil Science prize went to University of Zurich researchers who enlisted citizen scientists in over 25 nations to bury and later dig up 1,000 pairs of underwear to gauge soil health.
- Researchers at the University of Zurich developed the BioTAK score, combining blood biomarkers and biological sex to identify Takotsubo syndrome before cardiac catheterization. - An independent validation study of nearly 1,800 patients showed the score correctly classified almost 90 percent of participants even before invasive testing. - The score incorporates two novel biomarkers pointing to the brain-heart axis and an atherosclerosis-independent disease mechanism distinct from classic heart attack. - The tool is not intended to replace catheterization when medically necessary, but may guide diagnostics and avoid unnecessary invasive tests in selected patients.
- Researchers at the University of Zurich identified a specialized population of "regenerative" astrocytes in living mice that rebuild damaged brain tissue after injury or autoimmune disease. - These cells send newly formed nuclei of daughter cells gliding across long distances through astrocyte extensions to repopulate damaged areas and knit the astrocyte network back together. - The findings overturn the long-held assumption that the adult brain cannot fully replace lost astrocytes, such as in neuromyelitis optica spectrum disorder. - The team identified numerous genes and signaling pathways temporarily activated during repair, offering potential future targets for influencing post-disease and post-injury regeneration.
- Researchers at the Paul Scherrer Institute have resolved a previously unknown asymmetric BRAF dimer conformation that forms during cell signaling, published in Molecular Cell. - The study provides the first high-resolution visualization of the active BRAF-MEK1 complex, revealing how the NtA sequence motif bridges two BRAF proteins of different shapes. - BRAF mutations drive roughly half of all melanomas and about seven percent of other cancers, with existing targeted therapies frequently losing effectiveness due to drug resistance. - The discovery opens new avenues for designing drugs that target BRAF in novel ways, potentially offering more treatment options when resistance to current therapies develops.
- Researchers at the University of Zurich have identified the first direct biomarkers of acute sleep deprivation in saliva using high-resolution mass spectrometry and machine learning. - The study identified 10 salivary metabolites that reliably distinguish sleep-deprived individuals from well-rested ones, with a predictive model achieving 94% accuracy. - A large-scale international field study is now underway to validate the biomarker set in over 1,000 samples from shift workers, women, and frequent drivers. - The findings could lead to a rapid, on-site test for objectively detecting fatigue, with potential applications in road safety and high-risk professions.
- Award-winning NIH-funded research demonstrates that Aclarion's Nociscan magnetic resonance spectroscopy technology can identify immune-associated biological signatures in chronic low back pain patients. - The study used Nociscan's MRS methodology to measure intradiscal propionic acid levels, revealing distinct systemic immune activation patterns in patients with Modic type 1 changes. - Findings suggest potential expansion of Nociscan's clinical applications beyond surgical decision support to include personalized treatment strategies based on biological pain mechanisms. - Research indicates that elevated propionic acid levels can identify patient subgroups with specific immune system activation, particularly involving B-cells that produce antibodies.
- MUVON Therapeutics achieved positive Phase 2 results for its muscle precursor cell-based therapy MPCCOL, meeting both primary and secondary endpoints with 87% treatment responder rate at six months. - The tissue-engineered therapy demonstrated a 60% overall reduction in incontinence episodes and 66% decrease in urinary leakage, with higher doses showing up to 71% and 76% improvements respectively. - The autologous treatment showed favorable safety profile with no serious adverse events related to the therapy, potentially offering an alternative to synthetic material implants for the 150 million women affected by stress urinary incontinence worldwide.
- University of Zurich researchers have identified a new function of the immune checkpoint inhibitor TIGIT, showing it promotes tissue healing through specific growth factor production in immune cells. - Mice lacking TIGIT developed significantly more tissue damage in blood vessel walls and liver during viral infections, confirming the protein's protective role against tissue damage. - The discovery reveals TIGIT's dual role in balancing immune defense with tissue protection, potentially opening new therapeutic avenues for chronic wounds and liver fibrosis treatment. - The findings could lead to innovative treatments that activate the TIGIT checkpoint to accelerate regenerative processes in various tissue-damaging conditions.
- CUTISS secured €57.9 million in Series C funding, bringing total capital raised to over €129.3 million to advance its personalized bioengineered skin graft denovoSkin through Phase 3 trials. - The company's denovoSkin therapy has received Orphan Drug Designation from Swissmedic, EMA, and FDA for burn treatment, with first Phase 3 data expected by end of 2026. - CUTISS signed a strategic collaboration with Rode Kruis Ziekenhuis burn center, which invested in the round and will potentially host the company's first international production facility. - The company is also preparing to launch VitiCell, a CE-marked medical device for vitiligo treatment, positioning itself as a leader in the growing tissue engineering sector.
- Arcturus Therapeutics will host a virtual presentation on June 30, 2025, featuring Phase 2 interim data for ARCT-810, an investigational mRNA therapeutic for ornithine transcarbamylase deficiency. - The presentation will review safety and pharmacodynamics data from multiple doses of ARCT-810 in adolescent and adult participants with OTC deficiency, the most common urea cycle disorder. - Leading experts Dr. Marshall Summar and Dr. Johannes Häberle will participate in the presentation, bringing decades of expertise in urea cycle disorders and metabolic medicine. - ARCT-810 has received multiple regulatory designations including Orphan Drug status and Fast Track designation from the FDA for treating this rare genetic condition affecting approximately 10,000 people in Europe and the U.S.
